Article

Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancer

2026-05-13

Abstract excerpt

Acquired resistance to endocrine therapy remains a primary obstacle in the clinical management of estrogen receptor-positive (ER+) breast cancer. While resistance is frequently accompanied by transcriptional rewiring and lineage plasticity, how specific pharmacological modalities dictate divergent resistance trajectories remains poorly understood. Here, we integrate multi-omic profiling, spanning bulk and single-c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 335672f2-ea22-5c75-8fa1-76072118e01a
DOI: 10.64898/2026.05.11.724242

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancerDOI 10.64898/2026.05.11.724242Read

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerSemantic proximity Read

Endocrine therapy resistance: new insights.Semantic proximity Read

Estrogen Receptor Alpha Dynamics and Plasticity During Endocrine ResistanceSemantic proximity Read

Single-cell transcriptomics reveals multi-step adaptations to endocrine therapySemantic proximity Read

Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goalsSemantic proximity Read

PML1-Mediated Feedforward Loop Through PI3K and MAPK Axes Drives Endocrine ResistanceSemantic proximity Read

Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectivesSemantic proximity Read

Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differencesSemantic proximity Read

Estrogen regulates divergent transcriptional and epigenetic cell states in breast cancerSemantic proximity Read

Combating subclonal evolution of resistant cancer phenotypes.Semantic proximity Read

A mechanistic model captures the emergence and implications of non-genetic heterogeneity and reversible drug resistance in ER+ breast cancer cellsSemantic proximity Read

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.Semantic proximity Read